{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:16:20Z","timestamp":1790072180995,"version":"4.0.1"},"reference-count":116,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Glutathione (GSH) has several roles in a cell, such as a reactive oxygen species (ROS) scavenger, an intervenient in xenobiotics metabolism and a reservoir of cysteine. All of these activities are important in the maintenance of normal cells homeostasis but can also constitute an advantage for cancer cells, allowing disease progression and resistance to therapy. Ovarian cancer is the major cause of death from gynaecologic disease and the second most common gynaecologic malignancy worldwide. In over 50 years, the overall survival of patients diagnosed with epithelial ovarian cancer has not changed, regardless of the efforts concerning early detection, radical surgery and new therapeutic approaches. Late diagnosis and resistance to therapy are the main causes of this outcome, and GSH is profoundly associated with chemoresistance to platinum salts, which, together with taxane-based chemotherapy and surgery, are the main therapy strategies in ovarian cancer treatment. Herein, we present some insights into the role of GSH in the poor prognosis of ovarian cancer, and also point out how some strategies underlying the dependence of ovarian cancer cells on GSH can be further used to improve the effectiveness of therapy.<\/jats:p>","DOI":"10.3390\/ijms19071882","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T10:40:50Z","timestamp":1530009650000},"page":"1882","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Glutathione in Ovarian Cancer: A Double-Edged Sword"],"prefix":"10.3390","volume":"19","author":[{"given":"Sofia C.","family":"Nunes","sequence":"first","affiliation":[{"name":"Centro de Estudos de Doen\u00e7as Cr\u00f3nicas (CEDOC), NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Campo M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular do Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1548-5907","authenticated-orcid":false,"given":"Jacinta","family":"Serpa","sequence":"additional","affiliation":[{"name":"Centro de Estudos de Doen\u00e7as Cr\u00f3nicas (CEDOC), NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade Nova de Lisboa, Campo M\u00e1rtires da P\u00e1tria 130, 1169-056 Lisboa, Portugal"},{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular do Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0968-0004(88)90148-X","article-title":"On the discovery of glutathione","volume":"13","author":"Meister","year":"1988","journal-title":"Trends Biochem. Sci."},{"key":"ref_2","first-page":"1683","article-title":"Sur un corps d\u2019origine organique hydrog\u00e9nant le soufre \u00e1 froid","volume":"106","year":"1888","journal-title":"CR Acad. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1016\/S0021-9258(19)77815-6","article-title":"Glutathione metabolism and its selective modification","volume":"263","author":"Meister","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Copley, S.D., and Dhillon, J.K. (2002). Lateral gene transfer and parallel evolution in the history of glutathione biosynthesis genes. Genome Biol., 3.","DOI":"10.1186\/gb-2002-3-5-research0025"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.mam.2008.08.009","article-title":"Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase","volume":"30","author":"Franklin","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-1007167","article-title":"Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine","volume":"18","author":"Ookhtens","year":"1998","journal-title":"Semin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cbf.1149","article-title":"The role of glutathione in cancer","volume":"22","author":"Balendiran","year":"2004","journal-title":"Cell Biochem. Funct."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/10408360500523878","article-title":"Glutathione in cancer biology and therapy","volume":"43","author":"Estrela","year":"2006","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0891-5849(99)00177-X","article-title":"Glutathione and its role in cellular functions","volume":"27","author":"Sies","year":"1999","journal-title":"Free Radic. Biol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/972913","article-title":"Role of Glutathione in Cancer Progression and Chemoresistance","volume":"2013","author":"Traverso","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0009-2797(98)00008-8","article-title":"Clinical studies of reversal of drug resistance based on glutathione","volume":"111\u2013112","author":"Calvert","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"ref_12","first-page":"4224","article-title":"Glutathione Metabolism as a Determinant of Therapeutic Efficacy: A Review","volume":"44","author":"Arrick","year":"1984","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0163-7258(91)90076-X","article-title":"Glutathione deficiency produced by inhibition of its synthesis, and its reversal; Applications in research and therapy","volume":"51","author":"Meister","year":"1991","journal-title":"Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","article-title":"The importance of glutathione in human disease","volume":"57","author":"Townsend","year":"2003","journal-title":"Biomed. Pharmacother."},{"key":"ref_15","first-page":"489","article-title":"Glutathione Metabolism and Its Implications for Health","volume":"134","author":"Wu","year":"2004","journal-title":"Environ. Health"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Enns, G.M., Moore, T., Le, A., Atkuri, K., Shah, M.K., Cusmano-Ozog, K., Niemi, A., and Cowan, T.M. (2014). Degree of Glutathione Deficiency and Redox Imbalance Depend on Subtype of Mitochondrial Disease and Clinical Status. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100001"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.redox.2016.11.010","article-title":"Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease","volume":"11","author":"Torres","year":"2017","journal-title":"Redox Biol."},{"key":"ref_18","unstructured":"Choi, I., Lee, P., Denney, D., and Lynch, S. (2016). Longitudinal changes of cerebral glutathione levels in patients with secondary progressive multiple sclerosis may reflect the clinical course of disease progression. Mult. Scler. J."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Choi, I.Y., Lee, P., Adany, P., Hughes, A.J., Belliston, S., Denney, D.R., and Lynch, S.G. (2018). In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis. Mult. Scler. J.","DOI":"10.1177\/1352458517711568"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc2946","article-title":"The genesis and evolution of high-grade serous ovarian cancer","volume":"10","author":"Bowtell","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/01.AOG.0000231680.58221.a7","article-title":"Patterns and progress in ovarian cancer over 14 years","volume":"108","author":"Chan","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shen, H., Fridley, B.L., Song, H., Lawrenson, K., Cunningham, J.M., Ramus, S.J., Cicek, M.S., Tyrer, J., Stram, D., and Larson, M.C. (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat. Commun, 4.","DOI":"10.1038\/ncomms2629"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1078-0432.CCR-12-2243","article-title":"New strategies in the treatment of ovarian cancer: Current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: Recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","article-title":"Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma","volume":"99","author":"Itamochi","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_31","first-page":"364","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"5","author":"Dasari","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ijc.21685","article-title":"Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo","volume":"119","author":"Alexandre","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Marullo, R., Werner, E., Degtyareva, N., Moore, B., Altavilla, G., Ramalingam, S.S., and Doetsch, P.W. (2013). Cisplatin induces a mitochondrial-ros response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081162"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.1999.17.3.1061","article-title":"Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death","volume":"17","author":"Dumontet","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ip, C.K.M., Li, S., Tang, M.H., Sy, S.K.H., and Ren, Y. (2016). Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress. Sci. Rep., 6.","DOI":"10.1038\/srep26788"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014Shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/MCB.21.20.6913-6926.2001","article-title":"Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress","volume":"21","author":"Benhar","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jinorgbio.2004.04.024","article-title":"Protein interactions with platinum\u2014DNA adducts: From structure to function","volume":"98","author":"Chaney","year":"2004","journal-title":"J. Inorg. Biochem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists\u2019 Group","volume":"78","author":"Aabo","year":"1998","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Siddik, Z.H. (2003). Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene, 7265\u20137279.","DOI":"10.1038\/sj.onc.1206933"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kelland, L.R. (2000). Preclinical perspectives on platinum resistance. Drugs, 59.","DOI":"10.2165\/00003495-200059004-00001"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/cncr.2820710224","article-title":"Mechanisms of drug resistance in ovarian cancer","volume":"71","author":"Johnson","year":"1993","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/bjc.1996.384","article-title":"The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients","volume":"74","author":"Hogarth","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.1996.133","article-title":"Glutathione-S-transferase activity and isoenzyme levels measured by two methods in ovarian cancer, and their value as markers of disease outcome","volume":"73","author":"Wrigley","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","article-title":"High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis","volume":"89","author":"Godwin","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/bjc.1993.321","article-title":"Glutathione S-transferase expression in benign and malignant ovarian tumours","volume":"68","author":"Green","year":"1993","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/gyno.2002.6617","article-title":"Cellular Glutathione Content, in Vitro Chemoresponse, and the Effect of BSO Modulation in Samples Derived from Patients with Advanced Ovarian Cancer","volume":"304","author":"Lewandowicz","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0344-0338(00)80048-5","article-title":"Immunohistochemical Analysis of Drug Resistance- associated Proteins in Ovarian Carcinomas","volume":"196","author":"Mayr","year":"2000","journal-title":"Pathol. Res. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0301-2115(00)00473-5","article-title":"Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors","volume":"96","author":"Satoh","year":"2001","journal-title":"Eur. J. Obs. Gynecol. Reprod. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s00428-005-1228-0","article-title":"Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients","volume":"447","author":"Surowiak","year":"2005","journal-title":"Virchows Arch."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents q","volume":"7281","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<521::AID-CNCR14>3.0.CO;2-5","article-title":"Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy","volume":"79","author":"Cheng","year":"1997","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjc.2014.386","article-title":"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines","volume":"111","author":"Sawers","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1039\/C6MB00250A","article-title":"A Tyrosine-Reactive Irreversible Inhibitor for Glutathione S-transferase Pi (GSTP1)","volume":"12","author":"Crawford","year":"2016","journal-title":"Mol. Biosyst."},{"key":"ref_56","first-page":"5225","article-title":"MicroRNA-133b targets glutathione S-transferase \u03c0 expression to increase ovarian cancer cell sensitivity to chemotherapy drugs","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1007\/s13277-015-4290-5","article-title":"HNF1B drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC)","volume":"37","author":"Nunes","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_58","first-page":"2066","article-title":"Glutathione Depletion by L-Buthionine Sulfoximine Antagonizes Taxol Cytotoxicity Glutathione Depletion by L-Buthionine Sulfoximine Antagonizes Taxol Cytotoxicity","volume":"53","author":"Liebmann","year":"1993","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10147-003-0318-8","article-title":"Platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma: Glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome","volume":"8","author":"Medeiros","year":"2003","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00167","article-title":"ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis","volume":"5","author":"Hong","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ygyno.2006.03.002","article-title":"Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation","volume":"103","author":"Satyan","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Harris, I.S., Treloar, A.E., Lam, C., and Mak, T.W. (2015). Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression Article Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell, 211\u2013222.","DOI":"10.1016\/j.ccell.2014.11.019"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/ars.2016.6633","article-title":"Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling","volume":"26","author":"Kirkpatrick","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wang, J., Jin, L., Li, X., Deng, H., Chen, Y., Lian, Q., Ge, R., and Deng, H. (2013). Gossypol induces apoptosis in ovarian cancer cells through oxidative stress. Mol. Biosyst., 9.","DOI":"10.1039\/c3mb25461e"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mehy.2017.01.014","article-title":"The promising anticancer drug 3-bromopyruvate is metabolized through glutathione conjugation which affects chemoresistance and clinical practice: An evidence-based view","volume":"100","author":"Baghdadi","year":"2017","journal-title":"Med. Hypotheses"},{"key":"ref_66","first-page":"4405","article-title":"Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis","volume":"10","author":"Gandham","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_67","first-page":"2391","article-title":"Acetaminophen Enhances Cisplatin- and Paclitaxel-mediated Cytotoxicity to SKOV3 Human Ovarian Carcinoma","volume":"33","author":"Wu","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1002\/anie.201801378","article-title":"Enzyme-MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy","volume":"57","author":"Lian","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_69","first-page":"593","article-title":"Multi-institutional phase 2 study of TLK286 (TELCYTATM, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer","volume":"286","author":"Kavanagh","year":"2005","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cbpa.2010.10.016","article-title":"Redox platforms in cancer drug discovery and development","volume":"15","author":"Tew","year":"2011","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2165\/11592590-000000000-00000","article-title":"Cellular redox pathways as a therapeutic target in the treatment of cancer","volume":"71","author":"Montero","year":"2011","journal-title":"Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/cbt.28557","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials","volume":"15","author":"Staropoli","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"42740","DOI":"10.18632\/oncotarget.8600","article-title":"Cancer drug resistance: Redox resetting renders a way","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.2004.03.086","article-title":"Antioxidants and cancer therapy: A systematic review","volume":"22","author":"Ladas","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00686237","article-title":"Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer","volume":"25","author":"Bohm","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1008211226339","article-title":"Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial","volume":"8","author":"Smyth","year":"1997","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.biomaterials.2009.01.026","article-title":"Reduction-sensitive polymers and bioconjugates for biomedical applications","volume":"30","author":"Meng","year":"2009","journal-title":"Biomaterials"},{"key":"ref_78","first-page":"307","article-title":"Noninvasive Imaging of Tumor Redox Status and Its Modification by Tissue Glutathione Levels 1","volume":"62","author":"Kuppusamy","year":"2002","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Li, J., Huo, M., Wang, J., Zhou, J., Mohammad, J.M., Zhang, Y., Zhu, Q., Waddad, A.Y., and Zhang, Q. (2011). Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. Biomaterials.","DOI":"10.1016\/j.biomaterials.2011.11.022"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.msec.2015.09.025","article-title":"Construction of polymer\u2014Paclitaxel conjugate linked via a disulfide bond","volume":"58","author":"Yan","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1039\/C7BM00052A","article-title":"Glutathione-responsive paclitaxel dimer nanovesicles with high drug content","volume":"5","author":"Pei","year":"2017","journal-title":"Biomater. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3109\/1061186X.2011.589435","article-title":"Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers","volume":"19","author":"Geldenhuys","year":"2011","journal-title":"J. Drug Target."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.actbio.2015.08.029","article-title":"Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid","volume":"26","author":"Yin","year":"2015","journal-title":"Acta Biomater."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1016\/j.biomaterials.2011.05.050","article-title":"Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery","volume":"32","author":"Li","year":"2011","journal-title":"Biomaterials"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bhattacharyya, S., Saha, S., Giri, K., Lanza, I.R., Nair, K.S., Jennings, N.B., Rodriguez-Aguayo, C., Lopez-Berestein, G., Basal, E., and Weaver, A.L. (2013). Cystathionine Beta-Synthase (CBS) Contributes to Advanced Ovarian Cancer Progression and Drug Resistance. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079167"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1073\/pnas.1306241110","article-title":"Tumor-derived hydrogen sulfide, produced by cystathionine-\u03b2-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer","volume":"110","author":"Szabo","year":"2013","journal-title":"PNAS Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.freeradbiomed.2015.05.024","article-title":"Role of cystathionine \u03b2-synthase in human breast Cancer","volume":"86","author":"Sen","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/pcmr.12312","article-title":"Role of the cystathionine \u03b3 lyase\/hydrogen sulfide pathway in human melanoma progression","volume":"28","author":"Panza","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gai, J.W., Qin, W., Liu, M., Wang, H.F., Zhang, M., Li, M., Zhou, W.H., Ma, Q.T., Liu, G.M., and Song, W.H. (2016). Expression profile of hydrogen sulfide and its synthases correlates with tumor stage and grade in urothelial cell carcinoma of bladder. Urol. Oncol. Semin. Orig. Investig., 34.","DOI":"10.1016\/j.urolonc.2015.06.020"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1667\/RR14177.1","article-title":"Radiation Exposure Promotes Hepatocarcinoma Cell Invasion through Epithelial Mesenchymal Transition Mediated by H2S\/CSE Pathway","volume":"185","author":"Pan","year":"2015","journal-title":"Radiat. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0","article-title":"Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells","volume":"89","author":"Schnelldorfer","year":"2000","journal-title":"Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1152\/physrev.00017.2011","article-title":"Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed","volume":"92","author":"Wang","year":"2012","journal-title":"Physiol. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.bcp.2013.08.064","article-title":"Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A","volume":"86","author":"Panopoulos","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1073\/pnas.1115634109","article-title":"Hydrogen sulfide (H2S) metabolism in mitochondria and its regulatory role in energy production","volume":"109","author":"Fu","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"R592","DOI":"10.1152\/ajpregu.00421.2012","article-title":"Thiosulfate: A readily accessible source of hydrogen sulfide in oxygen sensing","volume":"305","author":"Olson","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Cochrane, D.R., Hughes, C.S., Nazeran, T., Karnezis, A.N., McConechy, M.K., Morin, G.B., and Huntsman, D.G. (2016, January 12\u201313). Abstract AP12: Cysteine metabolism in clear cell ovarian cancer. Proceedings of the Ovarian Cancer Research Symposium, Seattle, WA, USA.","DOI":"10.1158\/1557-3265.OVCASYMP16-AP12"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Poisson, L.M., Munkarah, A., Madi, H., Datta, I., Hensley-Alford, S., Tebbe, C., Buekers, T., Giri, S., and Rattan, R. (2015). A metabolomic approach to identifying platinum resistance in ovarian cancer. J. Ovarian Res., 8.","DOI":"10.1186\/s13048-015-0140-8"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Okuno, S., Sato, H., Tamba, M., Wang, H., Sohda, S., Hamada, H., and Yoshikawa, H. (2003). Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br. J. Cancer, 951\u2013956.","DOI":"10.1038\/sj.bjc.6600786"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","article-title":"Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer","volume":"165","author":"Wang","year":"2016","journal-title":"Cell"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1089\/ars.2008.2089","article-title":"Molecular Mechanisms and Clinical Implications of Reversible Protein S-glutathionylation","volume":"10","author":"Mieyal","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates Ras pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_102","first-page":"1","article-title":"miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway","volume":"14","author":"Boersma","year":"2015","journal-title":"Mol. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"ref_104","first-page":"6505","article-title":"Unfolded protein response mediated JNK\/AP-1 signal transduction, a target for ovarian cancer treatment","volume":"8","author":"Zheng","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_105","unstructured":"Chen, R., Ngan, H., and Chan, D. (2016, January 1\u20132). The AMPK\/TAK1\/NF-kB signaling axis is indispensable for modulating ovarian cancer cell metabolism and peritoneal metastases. Proceedings of the 21st Research Postgraduate Symposium (RPS 2016), Hong Kong, China."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.yexcr.2013.11.011","article-title":"Cell cycle arrest or survival signaling through \u03b1v integrins, activation of PKC and ERK1\/2 lead to anoikis resistance of ovarian cancer spheroids","volume":"320","author":"Carduner","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_107","first-page":"1","article-title":"Activation of the PKC Pathway Stimulates Ovarian Cancer Cell Proliferation, Migration, and Expression of MMP7 and MMP101","volume":"89","author":"McCord","year":"2013","journal-title":"Biol. Reprod."},{"key":"ref_108","first-page":"1","article-title":"Activation of A2b adenosine receptor regulates ovarian cancer cell growth: Involvement of Bax\/Bcl-2 and caspase-3","volume":"9","author":"Hajiahmadi","year":"2015","journal-title":"Biochem. Cell Biol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Su, Y., Gao, L., Teng, L., Wang, Y., Cui, J., Peng, S., and Fu, S. (2013). Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K\/Akt and NF-kappaB\/MMP-2 signaling pathways. J. Transl. Med., 11.","DOI":"10.1186\/1479-5876-11-132"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Echevarr\u00eda-Vargas, I.M., Valiyeva, F., and Vivas-Mej\u00eda, P.E. (2014). Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1\/c-Jun pathway. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097094"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1038\/onc.2014.296","article-title":"P53 Protein Aggregation Promotes Platinum Resistance in Ovarian Cancer","volume":"34","author":"Soteras","year":"2015","journal-title":"Oncogene"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.ajpath.2012.12.031","article-title":"Type i to type II ovarian carcinoma progression: Mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer","volume":"182","author":"Wu","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cbpa.2015.11.004","article-title":"Covalent targeting of acquired cysteines in cancer","volume":"30","author":"Visscher","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2015.143","article-title":"APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells","volume":"6","author":"Mohell","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Nunes, S.C., Ramos, C., Lopes-Coelho, F., Sequeira, C.O., Silva, F., Gouveia-Fernandes, S., Rodrigues, A., Guimar\u00e3es, A., Silveira, M., and Abreu, S. (2018). Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. Sci. Rep., in press.","DOI":"10.1038\/s41598-018-27753-y"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Nunes, S.C., Lopes-Coelho, F., Gouveia-Fernandes, S., Ramos, C., Pereira, S.A., and Serpa, J. (2018). Cysteine boosters the evolutionary adaptation to CoCl2 mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer. BMC Evol. Biol., in press.","DOI":"10.1186\/s12862-018-1214-1"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/1882\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:17Z","timestamp":1760195417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/7\/1882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7]]}},"alternative-id":["ijms19071882"],"URL":"https:\/\/doi.org\/10.3390\/ijms19071882","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]}}}